Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 17,845 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Patient Control Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Yo Puedo + mHealth; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Parkinson Disease
Interventions: Digital Speech Application; Device
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo for dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more

Conditions: Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Interventions: Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Graft vs Host Disease
Interventions: ASEDs, Saline; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Decompensated Heart Failure
Interventions: multi-domain rehabilitation intervention, Attention Control; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Durham, North Carolina • Winston-Salem, North Carolina • Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 29
States / cities: Escondido, California • Greenbrae, California • Los Angeles, California + 25 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dyspnea After Interscalene Nerve Block
Interventions: Maximum Inspiratory Pressure monitoring; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Urinary Tract Infections, Vaginal Flora Imbalance
Interventions: BioNourish; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: Up to 89 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Overactive Bladder, Urinary Tract Infection
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Pain
Interventions: bupivicaine epidural, bupivicaine epidural infusion patient epidural, bupivicaine; Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
Interventions: Cardiac Magnetic Resonance Imaging, ZioPatch Monitoring, Myocardial Tissue Biopsy; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Neurogenic Bladder
Interventions: Educational video; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Years to 99 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Chronic Pain, Low Back Pain, Radiculopathy, Complex Regional Pain Syndrome (CRPS)
Interventions: High frequency stimulation, Low frequency stimulation; Other
Lead sponsor: The Center for Clinical Research, Winston-Salem, NC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Helicobacter Pylori Infection
Interventions: Amoxicillin, Omeprazole, Clarithromycin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 51
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more

Conditions: Atrial Fibrillation, Stroke
Interventions: Computer Electronic Alert; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Interstitial Lung Disease
Interventions: efzofitimod 450 mg, efzofitimod 270 mg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 10 more

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more

Conditions: Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions: Rapid respiratory pathogen nucleic acid amplification test; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 1 Year to 101 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cancer, Inflammatory Disease, Vascular Diseases, Metabolic Bone Disease
Interventions: PHOTON COUNTING CT Scanner; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City

A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients

A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients

A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Preoperative Maximum Inspiratory Pressure and Outcomes After Interscalene Block in Obese Patients

Vaginal Care System for Menopausal Women With Urinary Tract Infections

Urinary Cytokines in Patients With Overactive Bladder (OAB)

Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes

PRIMARY Ancillary Substudy

Educational Video for Neurogenic Bladder

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

Study of JK07 in Patients With Chronic Heart Failure

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

Translational Development of Photon-counting CT Imaging